🏛️ Verified NIH Record • Updated 2026-05-21
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (NCT03808558)
A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: David E Gerber
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Who can join: Review the eligibility criteria below.
Location: University of Cincinnati — Cincinnati, Ohio
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- University of Cincinnati — Cincinnati, Ohio
- University of Texas Southwestern Medical Center — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in KRAS Gene Mutation
Explore by condition: All KRAS Gene Mutation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.